Business
Letter to Shareholders – 2025 a year of progress
Poolbeg Pharma plc reported significant progress in 2025, highlighted by an oversubscribed £4.865 million fundraise in June, extending its cash runway into 2027 with a £10.0 million cash balance as of June 30, 2025. The company is advancing its POLB 001 TOPICAL trial, which has secured teclistamab from Johnson & Johnson at no cost and is set to begin with interim data expected in summer 2026. Additionally, topline data for its oral GLP-1 program in obese subjects is anticipated in the first half of 2026, with the company actively pursuing partnering discussions for POLB 001, which addresses a potential market exceeding US$10 billion. Disclaimer*
About this update from Poolbeg Pharma Plc
[{"type":"text","content":"\n\n\n \nPoolbeg Pharma plc\n \nLetter to Shareholders - 2025 a year of great progress, with momentum maintained into 2026 when multiple value inflection points are expected\n \n18 December 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, publishes an end of year letter from the Company's Executive Chair, Cathal Friel, providing an overview of the significant progress made by the Company in 2025 and outlook for 2026.\n \nDear Shareholders,\n \nAs 2025 draws to a close, we wanted to reflect on the substantial progress made by Poolbeg this year, as we move POLB 001 into the clinic and anticipate data readouts from multiple clinical trials in 2026.\n \nOur oversubscribed and upsized fundraise in June 2025 raised gross proceeds of £4.865 million, extending our cash runway into 2027. The Company's cash balance of £10.0 million (as at 30 June 2025) will support the delivery of multiple key clinical milestones. To align resourcing with these near-term clinical priorities, the Company implemented a series of operational efficiency measures, including selective headcount reductions during the year. \n \nPOLB 001 - Upcoming TOPICAL trial \nPreparations for the forthcoming POLB 001 TOPICAL trial have advanced at pace, with multiple key milestones achieved in rapid succession:\n\n\n\n\n· \n\n\nSecured the approved bispecific antibody, teclistamab, for the study from Johnson & Johnson, a top-five global pharmaceutical company, at no cost to the Company\n\n\n\n\n· \n\n\nSigned an agreement for Accelerating Clinical Trials (ACT) to conduct the trial, led by Dr Emma Searle, Consultant Haematologist at The Christie NHS Foundation Trust\n\n\n\n\n· \n\n\nConfirmed participation from a number of additional cancer centres, including the NHS Foundation Trusts at The Royal Marsden, University College London Hospitals, and University Hospitals Birmingham\n\n\n\n\n· \n\n\nFinalised the protocol and preparing POLB 001 shipment to trial sites\n\n\n\n\n· \n\n\nSingle-arm, open-label design enables early insights and safety assessment; interim data expected in summer 2026\n\n\n\n...